Author: ["Weiping Zou","Véronique Machelon","Aurore Coulomb-L'Hermin","Jozef Borvak","Françoise Nome","Tatyana Isaeva","Shuang Wei","Roman Krzysiek","Ingrid Durand-Gasselin","Alan Gordon","Terri Pustilnik","David T. Curiel","Pierre Galanaud","Frédérique Capron","Dominique Emilie","Tyler J. Curiel"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Dendritic-cell (DC) trafficking and function in tumors is poorly characterized, with studies confined to myeloid DCs (DC1s). Tumors inhibit DC1 migration and function, likely hindering specific immunity. The role of plasmacytoid DCs (DC2s) in tumor immunity is unknown. We show here that malignant human ovarian epithelial tumor cells express very high levels of stromal-derived factor-1, which induces DC2 precursor (preDC2) chemotaxis and adhesion/transmigration, upregulates preDC2 very late antigen (VLA)-5, and protects preDC2s from tumor macrophage interleukin-10–induced apoptosis, all through CXC chemokine receptor-4. The VLA-5 ligand vascular-cell adhesion molecule-1 mediated preDC2 adhesion/transmigration. Tumor preDC2s induced significant T-cell interleukin-10 unrelated to preDC2 differentiation or activation state, and this contributed to poor T-cell activation. Myeloid precursor DCs (preDC1s) were not detected. Tumors may weaken immunity by attracting preDC2s and protecting them from the harsh microenvironment, and by altering preDC1 distribution.Cite this article
Zou, W., Machelon, V., Coulomb-L'Hermin, A. et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7, 1339–1346 (2001). https://doi.org/10.1038/nm1201-1339 